Biological response modifiers in photochemically pathogen-reduced versus untreated apheresis platelet concentrates

Transfusion

Volumn 53, Issue 1, 2013, Pages 147-155

  Vetlesen, Annette ^a   Mirlashari, Mohammad Reza ^b   Akkök, Çiǧdem Akalin ^b   Kelher, Marguerite R ^b   Khan, Samina Y ^b   Silliman, Christopher C ^b   Kjeldsen Kragh, Jens ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; CARBON DIOXIDE; CD40 LIGAND; FORMYLMETHIONYLLEUCYLPHENYLALANINE; INTERLEUKIN 10; LACTIC ACID; LIPOPOLYSACCHARIDE; OXYGEN; POTASSIUM; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; THROMBOCYTE CONCENTRATE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ARTICLE; BLOOD PH; CLINICAL ARTICLE; COMPARATIVE STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; GLUCOSE INTAKE; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUTROPHIL; PATHOGEN REDUCTION; PHOTOCHEMISTRY; THROMBOCYTE COUNT; THROMBOCYTE VOLUME; THROMBOCYTOPHERESIS;

BLOOD COMPONENT REMOVAL; BLOOD PLATELETS; HUMANS; HYDROGEN-ION CONCENTRATION; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; PHOTOCHEMISTRY; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84872271906     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03681.x     Document Type: Article

References (36)

1. Silliman CC, Thurman GW, Ambruso DR,. Stored blood components contain agents that prime the neutrophil NADPH oxidase through the platelet-activating- factor receptor. Vox Sang 1992; 63: 133-6.
2. Heddle NM,. Pathophysiology of febrile nonhemolytic transfusion reactions. Curr Opin Hematol 1999; 6: 420-6.
3. Cognasse F, Boussoulade F, Chavarin P, Acquart S, Fabrigli P, Lamy B, Garraud O,. Release of potential immunomodulatory factors during platelet storage. Transfusion 2006; 46: 1184-9.
4. Blajchman MA,. Transfusion immunomodulation or TRIM: what does it mean clinically? Hematology 2005; 10 Suppl 1: 208-14.
5. Silliman CC, Dickey WO, Paterson AJ, Thurman GW, Clay KL, Johnson CA, Ambruso DR,. Analysis of the priming activity of lipids generated during routine storage of platelet concentrates. Transfusion 1996; 36: 133-9.
6. Khan SY, Kelher MR, Heal JM, Blumberg N, Boshkov LK, Phipps R, Gettings KF, McLaughlin NJ, Silliman CC,. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood 2006; 108: 2455-62.
7. Silliman CC, McLaughlin NJ,. Transfusion-related acute lung injury. Blood Rev 2006; 20: 139-59.
8. Blumberg N, Gettings KF, Turner C, Heal JM, Phipps RP,. An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions. Transfusion 2006; 46: 1813-21.
9. Kaufman J, Spinelli SL, Schultz E, Blumberg N, Phipps RP,. Release of biologically active CD154 during collection and storage of platelet concentrates prepared for transfusion. J Thromb Haemost 2007; 5: 788-96.
10. FDA. Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year 2010. 2011. [cited 2012 Jan 10]. Available from: URL: http://www.fda.gov/BiologicsBloodVaccines/ SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/ucm254802.htm
11. Kanter J, Khan SY, Kelher M, Gore L, Silliman CC,. Oncogenic and angiogenic growth factors accumulate during routine storage of apheresis platelet concentrates. Clin Cancer Res 2008; 14: 3942-7.
12. Arisato T, Hashiguchi T, Sarker KP, Arimura K, Asano M, Matsuo K, Osame M, Maruyama I,. Highly accumulated platelet vascular endothelial growth factor in coagulant thrombotic region. J Thromb Haemost 2003; 1: 2589-93.
13. Blajchman MA,. Immunomodulation and blood transfusion. Am J Ther 2002; 9: 389-95.
14. Opelz G, Terasaki PI,. Dominant effect of transfusions on kidney graft survival. Transplantation 1980; 29: 153-8.
15. Blajchman MA, Bordin JO,. Mechanisms of transfusion-associated immunosuppression. Curr Opin Hematol 1994; 1: 457-61.
16. Burrows L, Tartter P, Aufses A,. Increased recurrence rates in perioperatively transfused colorectal malignancy patients. Cancer Detect Prev 1987; 10: 361-9.
17. Vamvakas EC, Blajchman MA,. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood 2001; 97: 1180-95.
18. Blumberg N,. Deleterious clinical effects of transfusion immunomodulation: proven beyond a reasonable doubt. Transfusion 2005; 2 Suppl: 33S-9S.
19. van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H, Vermeij H, Kappers-Klunne M, de Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L,; euroSPRITE trial. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101: 2426-33.
20. Snyder E, McCullough J, Slichter SJ, Strauss RG, Lopez-Plaza I, Lin JS, Corash L, Conlan MG,. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005; 45: 1864-75.
21. Hervig T, Seghatchian J, Apelseth TO,. Current debate on pathogen inactivation of platelet concentrates-to use or not to use? Transfus Apher Sci 2010; 43: 411-4.
22. van der Meer PF, Liefting LA, Pietersz RN,. The effect of interruption of agitation on in vitro measures of platelet concentrates in additive solution. Transfusion 2007; 47: 955-9.
23. Vetlesen A, Mirlashari MR, Torsheim IA, Kjeldsen-Kragh J,. Platelet activation and residual activation potential during storage of hyperconcentrated platelet products in two different platelet additive solutions. Transfusion 2005; 45: 1349-55.
24. Widing L, Bechensteen AG, Mirlashari MR, Vetlesen A, Kjeldsen-Kragh J,. Evaluation of nonleukoreduced red blood cell transfusion units collected at delivery from the placenta. Transfusion 2007; 47: 1481-7.
25. McLaughlin NJ, Banerjee A, Kelher MR, Gamboni-Robertson F, Hamiel C, Sheppard FR, Moore EE, Silliman CC,. Platelet-activating factor-induced clathrin-mediated endocytosis requires beta-arrestin-1 recruitment and activation of the p38 MAPK signalosome at the plasma membrane for actin bundle formation. J Immunol 2006; 176: 7039-50.
26. Bligh EG, Dyer WJ,. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911-7.
27. European Committee (Partial Agreement) on Blood Transfusion (CD-P-TS). Guide to the preparation, use and quality assurance of blood components. 16th ed. 2010. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe; 2011.
28. Kerkhoffs JL, van Putten WL, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, van Pampus LC, de Greef GE, Luten M, Huijgens PC, Brand A, van Rhenen DJ,; Dutch-Belgian HOVON cooperative group. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010; 150: 209-17.
29. Blair P, Flaumenhaft R,. Platelet alpha-granules: basic biology and clinical correlates. Blood Rev 2009; 23: 177-89.
30. Ferrara N, Gerber HP,. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 2001; 106: 148-56.
31. Phipps RP, Kaufman J, Blumberg N,. Platelet derived CD154 (CD40 ligand) and febrile responses to transfusion. Lancet 2001; 357: 2023-4.
32. Silliman CC, Bjornsen AJ, Wyman TH, Kelher M, Allard J, Bieber S, Voelkel NF,. Plasma and lipids from stored platelets cause acute lung injury in an animal model. Transfusion 2003; 43: 633-40.
33. Ambruso DR, Thurman G, Tran K, Marschner S, Gathof B, Janetzko K, Goodrich RP,. Generation of neutrophil priming activity by cell-containing blood components treated with pathogen reduction technology and stored in platelet additive solutions. Transfusion 2011; 51: 1220-7.
34. Silliman CC, Khan SY, Ball JB, Kelher MR, Marschner S,. Mirasol Pathogen Reduction Technology treatment does not affect acute lung injury in a two-event in vivo model caused by stored blood components. Vox Sang 2010; 98: 525-30.
35. Blumberg N, Heal JM, Rowe JM,. A randomized trial of washed red blood cell and platelet transfusions in adult acute leukemia (ISRCTN76536440). BMC Blood Disord 2004; 4: 6.
36. Cholette JM, Henrichs KF, Alfieris GM, Powers KS, Phipps R, Spinelli SL, Swartz M, Gensini F, Daugherty LE, Nazarian E, Rubenstein JS, Sweeney D, Eaton M, Lerner NB, Blumberg N,. Washing red blood cells and platelets transfused in cardiac surgery reduces postoperative inflammation and number of transfusions: results of a prospective, randomized, controlled clinical trial. Pediatr Crit Care Med 2011 Sep 15 [E-pub ahead of print].